Study of the safety and effectiveness of Tecovirimat for the treatment of Human MonkeyPox Virus Disease (STOMP)
Lay Description
To determine the difference in time to recovery and healing of monkey pox lesions between people receiving Tecovirimat and those receiving placebo. People with severe cases of monkeypox will receive Tecovirimat and not placebo.
Category
- Skin Conditions
- IRB Number
- 20220654HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- 18-99
- Eligible Genders
- All
- Accepts Healthy Volunteers
Inclusion Criteria
Illness < 14 days before study entry, have at least 1 active (not scabbed) lesion
Exclusion Criteria
Illness < 14 days before study entry, have at least 1 active (not scabbed) lesion
Study Design
Arm Groups
Study Contact
Thomas Patterson
(210) 567-4666
patterson@uthscsa.edu
Irma Scholler
+1 (210) 450-3150
scholler@uthscsa.edu
Robin Tragus
(210) 567-5262
tragus@uthscsa.edu
Thomas Patterson
(210) 567-4666
patterson@uthscsa.edu
Robin Tragus
(210) 567-5262
tragus@uthscsa.edu
Principal Investigator
Thomas Patterson